The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma

Paul G. Richardson, Philippe Moreau, Jacob P. Laubach, Neeraj Gupta, Ai Min Hui, Kenneth C. Anderson, Jesús F. San Miguel, Shaji Kumar

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Ixazomib is an investigational, reversible 20S proteasome inhibitor. It is the first oral proteasome inhibitor under clinical investigation in multiple myeloma (MM). Under physiological conditions, the stable citrate ester drug substance, ixazomib citrate (MLN9708), rapidly hydrolyzes to the biologically active boronic acid, ixazomib (MLN2238). Preclinical studies have demonstrated antitumor activity in MM cell lines and xenograft models. In Phase I/II clinical studies ixazomib has had generally manageable toxicities, with limited peripheral neuropathy observed to date. Preliminary data from these studies indicate ixazomib is active as a single agent in relapsed/refractory MM and as part of combination regimens in newly diagnosed patients. Phase III studies in combination with lenalidomide-dexamethasone are ongoing.

Original languageEnglish (US)
Pages (from-to)1153-1168
Number of pages16
JournalFuture Oncology
Issue number8
StatePublished - Apr 1 2015


  • continuous therapy
  • induction
  • multiple myeloma
  • newly diagnosed
  • oral administration
  • proteasome inhibition
  • refractory
  • relapsed

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this